13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
114 檔
18.3%
In Q2 2025, Ikarian Capital, LLC's U.S. equity holdings reached a combined market value of $928.2M, distributed across 114 disclosed stock positions.
In Q2 2025, Ikarian Capital, LLC adopted a defensive or profit-taking posture, trimming 32 positions and completely liquidating 52 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | Stock-Other | 12.04% | — | +417.03% | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.44% | -0.94% | EXIT | |
| 3 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 6.03% | -0.22% | +100.68% | |
| 4 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.19% | +1.51% | +256.94% | |
| 5 | CAPR | Capricor Therapeutics Inc | Stock-Other | 3.93% | +0.31% | +415.05% | |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.54% | — | +79.13% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 3.17% | -0.06% | EXIT | |
| 8 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.71% | — | +7.92% | |
| 9 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.67% | — | +12.95% | |
| 10 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.67% | — | +351.98% | |
| 11 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.62% | — | +52.91% | |
| 12 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.57% | — | +362.00% | |
| 13 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.43% | -6.65% | EXIT | |
| 14 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.39% | — | -17.19% | |
| 15 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.29% | +0.01% | +125.00% | |
| 16 | ✓ | Uniqure NV | Stock-Other | 2.14% | -0.22% | — | |
| 17 | PCVX | Vaxcyte Inc | Stock-Other | 1.95% | +0.41% | +55.95% | |
| 18 | COGT | Cogent Biosciences Inc | Stock-Other | 1.79% | +1.54% | NEW | |
| 19 | ACOG | Alpha Cognition Inc | Stock-Other | 1.64% | +0.18% | -5.17% | |
| 20 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.53% | +0.03% | -59.48% | |
| 21 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.45% | — | -0.06% | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.30% | -0.06% | EXIT | |
| 23 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.27% | -0.24% | +381.03% | |
| 24 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.26% | +0.84% | NEW | |
| 25 | ARVN | Arvinas Inc | Stock-Other | 1.20% | +0.01% | +269.73% | |
| 26 | FBRX | Forte Biosciences Inc | Stock-Other | 1.18% | -0.20% | -21.80% | |
| 27 | VIR | Vir Biotechnology Inc | Stock-Other | 1.03% | -0.21% | EXIT | |
| 28 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.01% | — | -56.66% | |
| 29 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.87% | — | -16.02% | |
| 30 | DCTH | Delcath Systems Inc | Stock-Other | 0.84% | -0.07% | +221.22% | |
| 31 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.82% | -0.19% | EXIT | |
| 32 | ✓ | Biohaven LTD | Stock-Other | 0.81% | — | — | |
| 33 | CGON | Cg Oncology Inc | Stock-Other | 0.77% | — | — | |
| 34 | VERA | Vera Therapeutics Inc | Stock-Other | 0.76% | +0.87% | — | |
| 35 | STIM | Neuronetics Inc | Stock-Other | 0.74% | +0.02% | -0.03% | |
| 36 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.73% | — | -30.67% | |
| 37 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.72% | — | — | |
| 38 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.67% | — | -33.34% | |
| 39 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.64% | — | — | |
| 40 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.62% | +0.36% | -39.17% | |
| 41 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.62% | +0.27% | -18.59% | |
| 42 | ALT | Altimmune Inc | Stock-Other | 0.62% | — | +244.79% | |
| 43 | JANX | Janux Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 44 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.52% | — | -2.44% | |
| 45 | BIIB | Biogen Inc | Stock-Healthcare | 0.52% | — | — | |
| 46 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.50% | -0.06% | EXIT | |
| 47 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 48 | ARCT | Arcturus Therapeutics Holdin | Stock-Other | 0.44% | — | -46.15% | |
| 49 | GERN | Geron CORP | Stock-Other | 0.43% | — | +966.67% | |
| 50 | KOD | Kodiak Sciences Inc | Stock-Other | 0.43% | +1.13% | -7.70% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | +11.4% | +417.03% | Add |
| 2 | RARE | Ultragenyx Pharmaceutical In | +4.1% | +100.68% | Add |
| 3 | PRAX | Praxis Precision Medicines I | +3.5% | +256.94% | Add |
| 4 | CAPR | Capricor Therapeutics Inc | +3.5% | +415.05% | Add |
| 5 | SLNOEUR | Soleno Therapeutics Inc | +3.4% | +16.62% | Add |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | +2.5% | +79.13% | Add |
| 7 | INSM | Insmed Inc | +2.4% | +93.10% | Add |
| 8 | APGE | Apogee Therapeutics Inc | +2.3% | +351.98% | Add |
| 9 | ✓ | Uniqure NV | +2.1% | NEW | New buy |
| 10 | COGT | Cogent Biosciences Inc | +1.8% | NEW | New buy |
| 11 | MLTX | Moonlake Immunotherapeutics | +1.7% | +52.91% | Add |
| 12 | VKTX | Viking Therapeutics Inc | +1.7% | +125.00% | Add |
| 13 | CYTK | Cytokinetics Inc | +1.7% | +155.67% | Add |
| 14 | VRNA | Verona Pharma PLC - Adr | +1.7% | +12.95% | Add |
| 15 | AKRO | Akero Therapeutics Inc | +1.5% | +7.92% | Add |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | +1.3% | NEW | New buy |
| 17 | SRPT | Sarepta Therapeutics Inc | +1.2% | +362.00% | Add |
| 18 | FULC | Fulcrum Therapeutics Inc | +1.2% | +381.03% | Add |
| 19 | PCVX | Vaxcyte Inc | +1% | +55.95% | Add |
| 20 | ACOG | Alpha Cognition Inc | +1% | -5.17% | Trim |
| 21 | ARVN | Arvinas Inc | +1% | +269.73% | Add |
| 22 | JAZZ | Jazz Pharmaceuticals plc | +0.8% | NEW | New buy |
| 23 | ✓ | Biohaven LTD | +0.8% | NEW | New buy |
| 24 | CGON | Cg Oncology Inc | +0.8% | NEW | New buy |
| 25 | VERA | Vera Therapeutics Inc | +0.8% | NEW | New buy |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | +0.7% | NEW | New buy |
| 27 | DCTH | Delcath Systems Inc | +0.7% | +221.22% | Add |
| 28 | FBRX | Forte Biosciences Inc | +0.6% | -21.80% | Trim |
| 29 | BIIB | Biogen Inc | +0.5% | NEW | New buy |
| 30 | 260 | Centessa Pharmaceuticals-adr | +0.5% | NEW | New buy |
| 31 | ALT | Altimmune Inc | +0.5% | +244.79% | Add |
| 32 | VRDN | Viridian Therapeutics Inc | +0.4% | -5.05% | Trim |
| 33 | TGTX | Tg Therapeutics Inc | +0.4% | -0.06% | Trim |
| 34 | GERN | Geron CORP | +0.4% | +966.67% | Add |
| 35 | ✓ | Proqr Therapeutics N.v. | +0.3% | NEW | New buy |
| 36 | SLN | Silence Therapeutics Plc-adr | +0.3% | NEW | New buy |
| 37 | TEVA | Teva Pharmaceutical-sp Adr | +0.3% | — | Unchanged |
| 38 | RLAY | Relay Therapeutics Inc | +0.3% | — | Unchanged |
| 39 | STIM | Neuronetics Inc | +0.2% | -0.03% | Trim |
| 40 | CRNX | Crinetics Pharmaceuticals In | +0.2% | -17.19% | Trim |
| 41 | VTYXUSD | Ventyx Biosciences Inc | +0.2% | -20.53% | Trim |
| 42 | KOD | Kodiak Sciences Inc | +0.2% | -7.70% | Trim |
| 43 | WVE | Wave Life Sciences Ltd. | +0.2% | NEW | New buy |
| 44 | VIR | Vir Biotechnology Inc | +0.2% | — | Unchanged |
| 45 | MAZE | Maze Therapeutics Inc | +0.2% | -18.59% | Trim |
| 46 | LXEO | Lexeo Therapeutics Inc | +0.2% | — | Unchanged |
| 47 | GPCR | Structure Therapeutics Inc | +0.2% | -30.67% | Trim |
| 48 | JANX | Janux Therapeutics Inc | +0.2% | — | Unchanged |
| 49 | IBB | Ishares Biotechnology ETF | +0.1% | NEW | New buy |
| 50 | CPRX | Catalyst Pharmaceuticals Inc | +0.1% | -16.02% | Trim |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 114 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CDTX, SLNOEUR, RARE) accounted for 18.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
UNIQURE NV
市值: $11.2M
Top Position Liquidated / Trimmed
SPY
前期市值: $193.0M
During Q2 2025, Ikarian Capital, LLC's top holdings by market value included CDTX (12.0%)、SLNOEUR (6.4%)、RARE (6.0%). The largest single position, CDTX, represented 12.0% of total portfolio value.
In Q2 2025, Ikarian Capital, LLC made 129 total portfolio adjustments, initiating 25 new buys, adding to 20 positions, trimming 32 holdings, and fully liquidating 52 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.